Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract.

Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections. The company has evaluated MAT2203 in clinical studies for conditions including cryptococcal meningitis and other invasive fungal infections. The product remains investigational and is not approved for commercial use.

The company has also developed additional LNC-based programs, including MAT2501, an investigational oral formulation of amikacin intended for potential use in treating certain difficult-to-manage bacterial infections. Matinas BioPharma is headquartered in the United States and has focused its activities on research, clinical development and potential partnerships for its drug-delivery platform and product candidates.

Key Stats

• Today's Range: $2.43 to $3.00
• 50-Day Range: $2.40 to $4.98
• 52-Week Range: $2.26 to $29.55
• Volume: 160,825 shs
• Average Volume: 137,567 shs
• Market Capitalization: $2.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Matinas Biopharma Stock Analysis - MarketRank™

Matinas Biopharma scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas Biopharma is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas Biopharma is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas Biopharma has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.15% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently increased by 41.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas Biopharma does not currently pay a dividend.

Dividend Growth

Matinas Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for MTNB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of Matinas Biopharma is held by insiders.

Percentage Held by Institutions

11.77% of the stock of Matinas Biopharma is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: matinasbiopharma.com
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 2
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -166.11%
• Return on Assets: -102.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 2.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.30 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 980,000
• Free Float: 935,000
• Market Cap: $2.59 million
• Optionable: N/A
• Beta: 2.08